A third, undisclosed Janssen program was also terminated.
Each party has regained all commercial rights for its respective drug discovery programs.
The OX-CLI and OX-ESI programs, focusing on discovering and developing innovative new treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases, will be closed.